J&J Gets Panel Date Seeking First A-Fib Ablation Catheter Indication
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's chances of becoming the first firm to market an ablation device in the U.S. labeled for treating atrial fibrillation will be clearer next month, when the company is scheduled to present PMA supplement data to an FDA advisory panel